Pioneering regenerative cell therapy to help stroke patients heal faster and regain quality of life
Amnio Bio is a biotech company that has developed an innovative cell-based therapy to transform stroke recovery. Using Human amniotic epithelial cells (hAECs) , this groundbreaking therapy supports healing and improves patient outcomes.
Amnio Bio aims to transform stroke recovery by helping patients to heal faster and regain quality of life.
Over 20 years of research has resulted in the development of the world’s first regenerative stroke therapy using Human Amniotic Epithelial Cells (hAECs) bringing hope to millions suffering the devastation of stroke.
Stroke occurs when blood flow to the brain is interrupted, causing brain cells to die within minutes.
A regenerative cell therapy designed to support brain repair and recovery after stroke.
Moving beyond damage control toward tissue repair and regeneration.
"Does no harm"
Establish dosage and efficacy in humans
Prof Sobey’s work represents a shift from time critical interventions to accessible cell therapy transfoprming stroke from a largely untreatable condition to mone with genuine repair potential. His translation from laboratory discovery to Phase 1 clinical trials establishes him as a glaobal pioneer in regenerative stroke therapy.
